VVIVEbiotech — Series A (estimated) · €1.1M
ViveBiotech develops and manufactures lentiviral vectors for gene therapy. It closed a new €1.1M round.
Lead not disclosed
RoundSeries A (estimated)
Announced15 Dec 2022
CitySan Sebastián
SectorHealthtech & Bio · Biotech / Viral vectors
Source
G
G
